Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Antroula Papakonstantinou

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2016
Is Estradiol Monitoring Necessary in Women Receiving Ovarian Suppression for Breast Cancer?Antroula Papakonstantinou, Theodoros Foukakis, Kenny A Rodriguez-Wallberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2016
Reply to A.Y. LinAntroula Papakonstantinou, Theodoros Foukakis, Kenny A Rodriguez-Wallberg, et al.
Lakartidningen|June 15, 2016
[Cardiotoxicity relatively common in cancer treatment]Eva Bühlmann Lerjen, Laila Hübbert, Antroula Papakonstantinou, et al.
Acta Oncologica (Stockholm, Sweden)|October 5, 2019
Neutropenic complications in the PANTHER phase III study of adjuvant tailored dose-dense chemotherapy in early breast cancerAntroula Papakonstantinou, Elham Hedayati, Mats Hellström, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|July 23, 2019
Outcome and presentation of heart failure in breast cancer patients: findings from a Swedish register-based studyElham Hedayati, Antroula Papakonstantinou, Sofie A M Gernaat, et al.
Cancer|December 19, 2019
Efficacy and safety of tailored and dose-dense adjuvant chemotherapy and trastuzumab for resected HER2-positive breast cancer: Results from the phase 3 PANTHER trialAntroula Papakonstantinou, Alexios Matikas, Nils Olof Bengtsson, et al.
British Journal of Cancer|February 13, 2019
Drug sensitivity testing on patient-derived sarcoma cells predicts patient response to treatment and identifies c-Sarc inhibitors as active drugs for translocation sarcomasBertha A Brodin, Krister Wennerberg, Elisabet Lidbrink, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2016
Is Estradiol Monitoring Necessary in Women Receiving Ovarian Suppression for Breast Cancer?Antroula Papakonstantinou, Theodoros Foukakis, Kenny A Rodriguez-Wallberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2016
Reply to A.Y. LinAntroula Papakonstantinou, Theodoros Foukakis, Kenny A Rodriguez-Wallberg, et al.
Lakartidningen|June 15, 2016
[Cardiotoxicity relatively common in cancer treatment]Eva Bühlmann Lerjen, Laila Hübbert, Antroula Papakonstantinou, et al.
Acta Oncologica (Stockholm, Sweden)|October 5, 2019
Neutropenic complications in the PANTHER phase III study of adjuvant tailored dose-dense chemotherapy in early breast cancerAntroula Papakonstantinou, Elham Hedayati, Mats Hellström, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|July 23, 2019
Outcome and presentation of heart failure in breast cancer patients: findings from a Swedish register-based studyElham Hedayati, Antroula Papakonstantinou, Sofie A M Gernaat, et al.
Cancer|December 19, 2019
Efficacy and safety of tailored and dose-dense adjuvant chemotherapy and trastuzumab for resected HER2-positive breast cancer: Results from the phase 3 PANTHER trialAntroula Papakonstantinou, Alexios Matikas, Nils Olof Bengtsson, et al.
British Journal of Cancer|February 13, 2019
Drug sensitivity testing on patient-derived sarcoma cells predicts patient response to treatment and identifies c-Sarc inhibitors as active drugs for translocation sarcomasBertha A Brodin, Krister Wennerberg, Elisabet Lidbrink, et al.
Pageof 1